Rabbit anti-PAI-1 Recombinant Monoclonal Antibody(214-43)

Rabbit anti-PAI-1 Recombinant Monoclonal Antibody(214-43)别名宿主反应种属应用免疫原形式浓度纯化方法类型克隆号储存/保存方法存储溶液背景说明UniProt

概述
别名
Plasminogen activator inhibitor 1; PAI; Serpin E1
宿主
Rabbit
反应种属
Human
应用
Sandwich ELISA
免疫原
Recombinant protein
性能
形式
Liquid
浓度
2 mg/ml
纯化方法
Protein A affinity column
类型
Monoclonal Antibody
克隆号
214-43
储存/保存方法
Store at 2 to 8℃ for one year.
存储溶液
PBS, pH 7.4, 0.03% Proclin 300
靶标
背景说明
Plasminogen activator inhibitor-1 (PAI-1) also known as endothelial plasminogen activator inhibitor or serpin E1 is a protein that in humans is encoded by the SERPINE1 gene. Elevated PAI-1 is a risk factor for thrombosis and atherosclerosis. PAI-1 is a serine protease inhibitor (serpin) that functions as the principal inhibitor of tissue plasminogen activator (tPA) and urokinase (uPA), the activators of plasminogen and hence fibrinolysis (the physiological breakdown of blood clots). It is a serine protease inhibitor (serpin) protein (SERPINE1). PAI-1’s main function entails the inhibition of urokinase plasminogen activator (uPA), an enzyme responsible for the cleavage of plasminogen to form plasmin. Plasmin mediates the degradation of the extracellular matrix either by itself or in conjunction with matrix metalloproteinases. In this scenario, PAI-1 inhibits uPA via active site binding, preventing the formation of plasmin. Additional inhibition is mediated by PAI-1 binding to the uPA/uPA receptor complex, resulting in the latter’s degradation. Thus, PAI can be said to inhibit the serine proteases tPA and uPA/urokinase, and hence is an inhibitor of fibrinolysis, the physiological process that degrades blood clots. In addition, PAI-1 inhibits the activity of matrix metalloproteinases, which play a crucial role in invasion of malignant cells through the basal lamina. PAI-1 is mainly produced by the endothelium (cells lining blood vessels), but is also secreted by other tissue types, such as adipose tissue. Increased levels of PAI-1 and tPA are associated with increased risk of cardiovascular disease, especially in patients with concomitant insulin resistance. It has been suggested that the tPA/PAI-1 complex would be an even stronger marker for thrombotic events than tPA antigen, and increased levels of tPA/PAI-1 complex were indeed recently shown to predict increased risk for first-ever stroke.
UniProt
P05121

实验结果图

Rabbit anti-PAI-1 Recombinant Monoclonal Antibody(214-43)

配对表格